Scott Mitchell
The Royal Marsden NHS Foundation Trust
5 Papers
8 Citations
Scott Mitchell is an academic researcher from The Royal Marsden NHS Foundation Trust. The author has contributed to research in topics: Ifosfamide & Gene mutation. The author has an hindex of 3, co-authored 5 publications.
Chat about Author
Papers
•Journal Article
A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience.
Charlotte Benson,Joanna Vitfell-Rasmussen,Marco Maruzzo,Cyril Fisher,Nina Tunariu,Scott Mitchell,Omar Al-Muderis,Khin Thway,James Larkin,Ian Judson +9 more
TL;DR: It is confirmed that mTOR inhibition with sirolimus/temsirolimous is well-tolerated with good radiological responses, albeit short-lived, and supports its use in PEComas.
82
The Royal Marsden Hospital experience of trabectedin in patients with advanced soft tissue sarcoma (STS): Toxicity and efficacy in a nonselected group.
Susana Banerjee,Scott Mitchell,Omar Al-Muderis,K. Pennert,Alison Dunlop,C. Propert-Lewis,Ian Judson,Michelle Scurr +7 more
TL;DR: This analysis of this largely non-selected STS cohort confirms the clinical activity of trabectedin, particularly in myxoid liposarcomas and synovial sarcomas, with approximately a third of patients experiencing prolonged disease control.
4
A retrospective study from the Royal Marsden Hospital (RMH) of patients with malignant perivascular epithelioid cell tumors (PEComa) receiving treatment with sirolimus (SI) or temsirolimus (TSI).
Joanna Vitfell Pedersen,Charlotte Benson,Nina Tunariu,Scott Mitchell,Cyril Fisher,Khin Thway,James Larkin,Michelle Scurr,Ian Judson +8 more
TL;DR: A retrospective analysis was performed on all pts with PEComa referred to the Sarcoma unit at RMH between 2000 and 2011 to report the outcome of 7 patients treated with SI or TSI atRMH.
3
Palliative ambulatory 14-day infusional ifosfamide in the outpatient setting for treatment of advanced soft tissue sarcomas (STS): “Old wine in a new bottle.”
Salma Alam,Charlotte Benson,David Olmos,Robin L. Jones,Scott Mitchell,Omar Al-Muderis,Alison Dunlop,C. Propert-Lewis,Michelle Scurr,Ian Judson +9 more
TL;DR: A retrospective review of patients treated with a prolonged 14 day infusional outpatient regimen of IFO for advanced sarcoma from September 2008 - December 2011 to determine toxicity and treatment response.
1
Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma
Juan Martin-Liberal,Salma Alam,Anastasia Constantinidou,Cyril Fisher,Komel Khabra,Christina Messiou,David Olmos,Scott Mitchell,Omar Al-Muderis,Aisha Miah,Mark Linch,Robin L. Jones,Michelle Scurr,Ian Judson,Charlotte Benson +14 more
TL;DR: Ifosfamide administered as a 14-day continuous infusion is a safe regimen in STS with notable activity in DDLPS, and neither hypoalbuminaemia nor gender was found to predict toxicity, although encephalopathy predominantly affected females.